Drugs / MHU650
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04635800 | Dec 2020 → May 2022 | diabetic macular edema, macular retinal edema, retinal vein occlusion, wet macular degeneration | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHU650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04635800 ↗ |
| Route | Intravitreal | “A single dose of MHU650 intravitreal injection will be administered” NCT04635800 ↗ |